<DOC>
	<DOCNO>NCT02023411</DOCNO>
	<brief_summary>Diabetic foot represent major medical , social economic problem worldwide . Charcot 's neuroarthropathy , common cause diabetic foot , intrigue topic research endocrinologists , podiatrist surgeon . After first description JEAN-MARTIN CHARCOT 1868 , many theory put forward regard pathophysiology , much research do prevention treatment , specially inactive stage . The course Charcot 's neuroarthropathy triphasic , diagnosis usually miss active stage , henceforth patient often come u deformed foot . As consequence , osteoclastic activity active stage render foot bone demineralize weak , thus susceptible fracture fragmentation . Teriparatide recombinant human ( 1-34 ) parathyroid molecule approve post-menopausal osteoporosis men primary secondary osteoporosis . It act preferentially stimulating osteoblast osteoclast activity result new bone formation increase rate bone remodel manifest increase skeletal mass bone mineral density . Keeping pathophysiology Charcot 's foot mind , teriparatide may use potential treatment inactive Charcot 's neuroarthropathy study randomize trial set , till date . We hypothesize teriparatide may increase remodel foot bone Charcot 's neuroarthropathy , improve bone mineral density , subsequently lead reduction risk fracture progression deformity . This study plan compare effect teriparatide diabetes patient inactive Charcot 's foot placebo control design .</brief_summary>
	<brief_title>Efficacy Teriparatide Diabetic Inactive Charcot Neuroarthropathy Foot</brief_title>
	<detailed_description>Charcot neuroarthropathy ( CN ) first describe Jean-Martin Charcot patient tabes dorsalis recognize peripheral neuropathy could lead neuropathic joint . This condition many name , include Charcot osteoarthropathy , neuropathic osteo- arthropathy , many others . Charcot foot may occur complication neurosyphilis , syringomyelia , leprosy , poliomyelitis , congenital neuropathy diabetes mellitus , latter currently common cause CN . Since description CN 1883 , pathophysiology remain enigma , strict guideline treatment disorder . India people live diabetes country world diabetic foot one common diabetic complication find India . The prevalence Charcot foot diabetes clearly know ( 0.1 % nearly 30 % ) , appreciated condition infrequent might generally think . CN characterize progressive destruction bone joint foot accompany osteopenia . The current belief disease trigger susceptible individual , mediated process uncontrolled inﬂammation foot . This inﬂammation lead osteolysis indirectly responsible progressive fracture dislocation characterize presentation . The pathophysiologic event cytokine- driven elevation receptor activator nuclear factor kappa B ligand ( RANKL ) , , turn , enhance synthesis nuclear factor kB ( NF-kB ) . The latter promotes osteoclast maturation osteoclastic activity , lead osteoporosis affect bone . In parallel , NF-kB enhances production osteoprotegerin osteoblast , order provide antagonist RANKL mitigate effect . Ultimately , cascade pathophysiologic change lead development Charcot 's foot demineralization bone . If condition correctly diagnose patient appropriately immobilize , local inflammation subside bony destruction include progressive loss mineral density may prevent . But diagnosis CN frequently miss active phase almost 25 % case . In inactive stage , sign local inﬂammation progressively recede , redness subsides , difference skin temperature two foot diminishes . Most patient come diabetes clinic present inactive phase stable foot deformity viz rocker bottom deformity , loss longitudinal transverse arch , bony prominence ( medial convexity ) significant demineralization bone . These foot deformity result abnormal high-pressure area particularly prone ulceration ; consequence continue weight bearing . Recombinant human parathyroid hormone fragment ( teriparatide ) anabolic therapy , preferentially stimulate osteoblast osteoclast activity result new bone formation increase rate bone remodel . These effect manifest increase skeletal mass , bone mineral density ( BMD ) bone strength , subsequently lead reduction risk fracture . It well establish teriparatide increase bone remodel skeleton histomorphometry study measurements bone turnover marker ( BTM ) , recently direct measurement effect teriparatide site-specific metabolic activity skeleton show patient osteoporosis . Radionuclide bone scan image use radiopharmaceutical 99Technetium-methylene diphosphonate ( MDP ) useful role clinical practice research investigate metabolic bone disease response treatment . In clinical practice , bone scan report solely qualitative visual interpretation image allow detection discrete change skeleton area focal tracer uptake . An increased 99mTc-MDP skeletal uptake teriparatide see patient osteoporosis indicate increase bone formation support BTM increase . Recently , quantitative bone scintigraphy MDP describe sensitive tool study bone-remodeling process even CN . The potential utility quantitative bone scan diagnosis importantly CN activity suggest . However , translate visual assessment quantitative data F18 PET/ SPECT CT study region interest ( ROI ) ass response teriparatide specific . The role teriparatide diabetes patient CN study , till date . Keeping pathophysiology CN mind , present study plan assess efficacy teriparatide chronic CN study change bone remodel quantitated F18 SPECT CT , BMD markers bone turnover . We also assess benefit teriparatide , , foot morbidity i.e incidence fracture , progression deformity need amputation follow period 18 month .</detailed_description>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Arthropathy , Neurogenic</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>1 . Clinical criterion : 1 . No warmth redness foot . 2 . Difference temperature two foot &lt; 2 degree Centigrade . 3 . If deformity present , patient able walk without aid . 4 . History resolve active Charcot 's neuroarthropathy foot . 2 . Radiological criterion : Plain Xray foot ( weight bear lateral oblique ) show least 3 follow feature 1 . Foot deformity . 2 . Joint subluxations/dislocations . 3 . Smoothening /Rounding bone fragment . 4 . Subchondral sclerosis/erosions . 5 . Callus formation . 6 . Joint space collapse . 1 . Active inflammatory phase Charcot 's neuroarthropathy . 2 . Active inactive Charcot 's neuroarthropathy . 3 . Osteomyelitis foot bone . 4 . Peripheral vascular disease . 5 . Osteoporosis ( T score less equal 2.5 lumbar spine hip ) . 6 . Renal failure ( estimate Glomerular Filtration Rate &lt; 60 ml/min ) . 7 . Previous/present bone malignancy . 8 . Previous malignancy metastases bone . 9 . Received teriparatide earlier . 10 . Hyperparathyroidism . 11 . Paget 's disease bone . 12 . Pregnant woman . 13 . Received bisphosphonates previous 18 month . 14 . Patients ulcer involved foot . 15 . Patients previously take Pioglitazone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Teriparatide</keyword>
	<keyword>Inactive Charcot 's neuroarthropathy</keyword>
</DOC>